Recommendations Developed for Lymphangioleiomyomatosis

Share this content:
Recommendations Developed for Lymphangioleiomyomatosis
Recommendations Developed for Lymphangioleiomyomatosis

WEDNESDAY, Nov. 9, 2016 (HealthDay News) -- In a Clinical Practice Guideline published in the American Journal of Respiratory and Critical Care Medicine, evidence-based recommendations are presented for the diagnosis and management of lymphangioleiomyomatosis (LAM).

Francis X. McCormack, M.D., from the University of Cincinnati, and colleagues performed systematic reviews to summarize the evidence relating to diagnosis and treatment of LAM. Evidence-based recommendations were formulated, written, and graded.

The authors considered the panel's confidence in the estimated effects, the balance of benefits versus harms and burdens of treatment, patient values and preferences, cost, and feasibility, and formulated recommendations for or against specific interventions. Recommendations included treatment with sirolimus rather than observation for patients with LAM with abnormal/declining lung function, and treatment with sirolimus before invasive management for selected patients with LAM with problematic chylous effusions. Vascular endothelial growth factor D testing was recommended to establish LAM diagnosis before consideration of diagnostic lung biopsy. Doxycycline and hormonal therapy were not recommended for LAM treatment.

"Evidence-based recommendations for the diagnosis and treatment of patients with LAM are provided," the authors write. "Frequent reassessment and updating will be needed."

Several authors disclosed financial ties to the biopharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

SABCS: Artificial Intelligence May Aid Doctors in Breast ...

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

Devices reduce blood flow to hair follicles during chemotherapy treatments

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

Women on aromatase inhibitors exhibit less elasticity in their blood vessels

is free, fast, and customized just for you!

Already a member?

Sign In Now »